Actuate Therapeutics, Inc. Common stock (ACTU) News
Track canonical SquawkNews coverage tagged to ACTU, Actuate Therapeutics, Inc. Common stock. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. NASDAQ:ACTU (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the t
EQUITY | Sep 09, 2026, 09:02 PM UTC
L
ACTU - Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
ACTU - Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 09:00 PM UTC
L
Actuate announces preclinical synergy for elraglusib with RAS inhibitors
Actuate Therapeutics said it announced new preclinical data showing synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
EQUITY | Sep 09, 2026, 11:01 AM UTC
L
Actuate announces preclinical combo synergy for elraglusib
Actuate said preclinical data show synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
EQUITY | Sep 09, 2026, 11:01 AM UTC